A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
8d agoen
From the article
Conditions : Biliary Tract Neoplasms Immunotherapy Interventions : Combination Product: Durvalumab plus GEMOX/GC chemotherapy sequentially followed by lenvatinib; Drug: Capecitabine Sponsors : Peking Union Medical College Hospital Recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study
doi.org·18d ago
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscape·18h ago
ClinicalKey
clinicalkey.com·1mo ago
Antibody-Drug Conjugates in Perioperative Treatment of Muscle-Invasive Bladder Cancer: Expert Perspectives
This article discusses the emerging role of antibody-drug conjugates (ADCs) in the perioperative treatment of muscle-invasive bladder cancer
mdsc.pe·8d agoSavolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'
Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the forma
sciencealert.com·29d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.